Qiagen NV (NASDAQ:QGEN) has earned an average rating of “Hold” from the sixteen research firms that are presently covering the stock, MarketBeat.com reports. Nine research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $34.88.
Several research analysts recently commented on QGEN shares. Deutsche Bank reiterated a “buy” rating on shares of Qiagen in a report on Monday, January 22nd. Zacks Investment Research downgraded shares of Qiagen from a “hold” rating to a “sell” rating in a report on Monday, December 11th. BidaskClub upgraded shares of Qiagen from a “hold” rating to a “buy” rating in a report on Wednesday, February 21st. Commerzbank reiterated a “buy” rating on shares of Qiagen in a report on Thursday, February 1st. Finally, DZ Bank reiterated a “neutral” rating on shares of Qiagen in a report on Tuesday, December 19th.
QGEN traded down $0.78 during trading on Friday, hitting $31.23. The stock had a trading volume of 456,369 shares, compared to its average volume of 1,085,496. Qiagen has a 12 month low of $27.74 and a 12 month high of $36.34. The company has a current ratio of 5.07, a quick ratio of 4.59 and a debt-to-equity ratio of 0.69.
Qiagen announced that its board has initiated a stock repurchase program on Wednesday, January 31st that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.
Hedge funds and other institutional investors have recently bought and sold shares of the business. American International Group Inc. acquired a new stake in Qiagen in the 4th quarter worth $154,000. Lourd Capital LLC acquired a new stake in Qiagen in the 4th quarter worth $223,000. Hartford Investment Management Co. acquired a new stake in Qiagen in the 3rd quarter worth $231,000. Trexquant Investment LP acquired a new stake in Qiagen in the 3rd quarter worth $234,000. Finally, Barings LLC acquired a new stake in Qiagen in the 3rd quarter worth $255,000. Institutional investors own 62.23% of the company’s stock.
Qiagen Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.